References
- National cancer center, cancer trend report 2021. Available from https://cancer.go.kr/download.do?uuid=71610cce-c1a7-457d-8ee6-09c93aacb330.pdf. Accessed February 25, 2023.
- Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 2009;13(4):331-8. https://doi.org/10.1016/j.ejpain.2008.06.014
- Koh S, Lee K, Oh S, Kang J, et al. Assessment, management, and barriers of breakthrough cancer pain: a nationwide study in Korea. Support Care Cancer 2019;27:eP064.
- Davies A, Buchanan A, Zeppetella G, et al. Breakthrough Cancer Pain: An Observational Study of 1000 European Oncology Patients. J Pain Symptom Manage. 2013;46(5):619-28. https://doi.org/10.1016/j.jpainsymman.2012.12.009
- Bae SB, Lee SC. Medical Treatment of Cancer Pain: Drug Therapy according to Guidelines Will Improve the Quality of Life of Cancer Patients. Korean J Med 2018;93(3):260-5. https://doi.org/10.3904/kjm.2018.93.3.260
- Bennett D, Burton AW, Fishman S, Fortner B, et al. Consensus panel recommendations for the assessment and management of breakthrough pain: Part 2 Management. P and T. 2005;30(6):354-61.
- HiNeca [Vol.65] Abuse of opioid, are we safe? Available from https://hineca.kr/1976 Accessed November 05 2022.
- Min Seok Seo, Jae Yong Shim Breakthrough Cancer Pain. Korean J Hosp Palliat Care 2015;18(1):1-8. https://doi.org/10.14475/kjhpc.2015.18.1.1
- IQVIA. Quintiles and IMS Health. Available from https://www.iqvia.com/locations/korea. Accessed February 25, 2023.
- Ju, C., Wei, L., Man, et al. Global, regional, and national trends in opioid analgesic consumption from 2015 to 2019: a longitudinal study. Lancet Public Health 2022;7(4):e335-46. https://doi.org/10.1016/S2468-2667(22)00013-5
- European Society for Medical Oncology. Cancer Pain Management Clinical Practice Guidelines 2018. Available from https://reference. medscape.com/viewarticle/902352. Accessed February 25, 2023.
- Shin J, Shim JY, Seo MS, et al. Factors Influencing Pain Medication Preference for Breakthrough Cancer Patients and Their Application to Treatments: Survey on Physicians. Korean J Hosp Palliat Care 2018;21(1):9-13. https://doi.org/10.14475/kjhpc.2018.21.1.9
- Mercadante S, Marchetti P, Cuomo A, Mammucari M, Caraceni A; IOPS MS study Group. Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group. Support Care Cancer. 2016;24(2):961-8. https://doi.org/10.1007/s00520-015-2951-y
- YS Rhee, SY Kim., JH Park. Financial Hardship Factors affecting the Cancer Patient's Quality of Life. Journal of the Korea Academia-Industrial cooperation Society. 2020;21(10):299-307. https://doi.org/10.5762/KAIS.2020.21.10.299
- Simon SM, Schwartzberg LS. A review of rapid-onset opioids for breakthrough pain in patients with cancer. J Opioid Manag. 2014; 10(3):207-15. https://doi.org/10.5055/jom.2014.0209
- Cortesi PA, D'Angiolella LS, Vellucci R, et al. Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment. PLoS One. 2017;12(6):e0179523.
- England R, Maddocks M, Manderson C, Zadora-Chrzastowska S, Wilcock A. How practical are transmucosal fentanyl products for breakthrough cancer pain? Novel use of placebo formulations to survey user opinion. BMJ Support Palliat Care. 2011;1(3):349-51. https://doi.org/10.1136/bmjspcare-2011-000037
- Janknegt R, van den Beuken M, Schiere S, et al. Rapid acting fentanyl formulations in breakthrough pain in cancer. Drug selection by means of the System of Objectified Judgement Analysis. Eur J Hosp Pharm. 2018;25(3):e2.
- Zeppetella G, Davies A, Eijgelshoven I, Jansen JP. A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes. J Pain Symptom Manage. 2014; 47(4):772-85. https://doi.org/10.1016/j.jpainsymman.2013.05.020
- Hayan Kwon. Cost-effectiveness analysis of opioid analgesics for treatment of breakthrough pain in cancer patients. M.S Thesis for Seoul National University Graduate School. 2012.
- Giuliani J, Fiorica F, Sacchetto A, Franceschini G, Vaccari F, Bonetti A. The role of fentanyl in the treatment of breakthrough cancer pain: Different biotechnologies, different results and different drug costs. J Oncol Pharm Pract. 2021;27(2):445-7. https://doi.org/10.1177/1078155220983429
- Shin J, Cho SJ, Lee J, Choi YS. Validation of the Korean Version of the Breakthrough Pain Assessment Tool in Cancer Patients. J Pain Symptom Manage. 2017;54(3):361-7. https://doi.org/10.1016/j.jpainsymman.2017.07.011
- Kwon MY, Cho HN, Koo DH, Lee YG, Oh S, Lee SS. Initial titration with 200 ㎍ fentanyl buccal tablets: a retrospective safety analysis in Korean cancer patients. Korean J Intern Med. 2018; 33(3):577-84. https://doi.org/10.3904/kjim.2016.044
- Choi YJ Factors associated with Breakthrough Pain in Cancer Patients, M.S Thesis for Kyung Hee University Graduate School. 2019.
- Kang JH, Koh SJ, Oh SY, et al. Interference with daily functioning by breakthrough pain in patients with cancer. Support Care Cancer. 2020;28(11):5177-83. https://doi.org/10.1007/s00520-020-05329-9